Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis

Clinical Proteomics

Helene Fachim¹  Adrian Heald²  Narges Azadbakht³  Nophar Geifman⁴  Silke Conen⁵  Bill Deakin⁶  Oliver Howes⁷  Sanam Farman⁸  Bethany Geary⁹  Dave Chi Hoo Lee⁹  Anthony Whetton^1,10 

[1] Department of Endocrinology, Salford Royal Hospital, Manchester, UK;Faculty of Biology, Medicine and Health and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK;Department of Endocrinology, Salford Royal Hospital, Manchester, UK;Faculty of Biology, Medicine and Health and Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK;Department of Diabetes and Endocrinology, Salford Royal Hospital, M6 8HD, Salford, UK;Division of Informatics, Imaging and Data Sciences, The University of Manchester, Manchester, UK;Division of Informatics, Imaging and Data Sciences, The University of Manchester, Manchester, UK;The Manchester Molecular Pathology Innovation Centre, The University of Manchester, Manchester, UK;Division of Medical Education, The University of Manchester, Manchester, UK;Division of Neuroscience and Experimental Psychology, The University of Manchester, Manchester, UK;IOP, Psychosis Studies, London, UK;Mersey Deanery Psychiatry Training Rotation, Manchester, UK;Stoller Biomarker Discovery Centre, The University of Manchester, Manchester, UK;Stoller Biomarker Discovery Centre, The University of Manchester, Manchester, UK;The Manchester Molecular Pathology Innovation Centre, The University of Manchester, Manchester, UK;

关键词: Schizophrenia;    Molecular approaches;    SWATH MS;    Weight change;   

DOI  :  10.1186/s12014-020-09299-2

来源: Springer

【 摘 要 】

Weight gain is a common consequence of treatment with antipsychotic drugs in early psychosis, leading to further morbidity and poor treatment adherence. Identifying tools that can predict weight change in early psychosis may contribute to better-individualised treatment and adherence. Recently we showed that proteomic profiling with sequential window acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry (MS) can identify individuals with pre-diabetes more likely to experience weight change in relation to lifestyle change. We investigated whether baseline proteomic profiles predicted weight change over time using data from the BeneMin clinical trial of the anti-inflammatory antibiotic, minocycline, versus placebo. Expression levels for 844 proteins were determined by SWATH proteomics in 83 people (60 men and 23 women). Hierarchical clustering analysis and principal component analysis of baseline proteomics data did not reveal distinct separation between the proteome profiles of participants in different weight change categories. However, individuals with the highest weight loss had higher Positive and Negative Syndrome Scale (PANSS) scores. Our findings imply that mode of treatment i.e. the pharmacological intervention for psychosis may be the determining factor in weight change after diagnosis, rather than predisposing proteomic dynamics.

【 授权许可】

CC BY